The replacement of lung function equipment may not result in changing values: transitions should be seamless. We compared the equipment of two manufacturers (ZAN and Jaeger) to estimate the differences in spirometry, bodyplethysmography and diffusion capacity derived parameters elicited by equipment differences, and also compared calibration systems. From Jaeger (1) a Masterlab bodyplethysmograph, (2) a Pneumoscreen pneumotachograph, (3) a Masterscreen CS-FRC and (4) a Masterlab CompactTransfer (the latter two measure the diffusion capacity) were compared, and from ZAN a bodyplethysmograph system encompassing spirometry, flow-volume curve and diffusion capacity measurements. In vitro (a 2 litre calibration syringe at three flows, a fixed flow generator (0.5 l s −1 , 1.67 l s −1 and 5 l s −1 ) and a wave form generator) studies and an in vivo cross-over study (N = 59) were used to compare the pneumotachographs. Other parameters were compared only via the in vivo study. The calibration syringe study showed no differences between the pneumotachographs: all volumes in all systems were within 3% of the reference. The fixed flow generator showed no flow differences either: again within 3% of the reference. The wave form generator showed PEF, MEF 75/50/25 differences up to 10-15% from the reference, but none in FEV 1 and FVC. The in vivo study found similar system differences in PEF, MEF 75/50/25 : up to 29%. FEV 1 , VC and FVC differed by small amounts (in all cases <3% between systems). R 0.5 , TLC, V A and RV differed by small amounts between the systems (in all cases <3%), but T L,CO up to 9%. This study showed that between and within manufacturers, significant differences can exist between pneumotachographs and that using calibration syringes or fixed flow generators these frequently go unnoticed. These approaches insufficiently test the dynamic features of pneumotachographs. For other parameters, in vivo calibration is the only option and accuracy is only achieved with rather large samples, so more research is needed into suitable in vitro systems.
Introduction
In lung function laboratories, often one particular brand of equipment is used and that system automatically becomes the 'golden standard' in the sense that all diagnostic and therapeutic decisions are based on the measurements with that equipment. One will, sooner or later, be faced with the problem that that equipment has to be replaced due to wear and tear, and alternative manufacturers come into play. Even, when one would opt to stay with one's original manufacturer, newer versions of the older equipment will be installed. Such a change of manufacturer/version may not lead to clinically relevant differences in the measurements: a FEV 1 value should not be dependent on the type of equipment (European Agency for the Evaluation of Medicinal Products 2001). Rephrased: new manufacturers or versions should be equivalent to the existing equipment (unless one knows that the older equipment did not measure correctly).
The approach to such comparisons can be either in vitro, in vivo or combined in vitro/ in vivo. Volume-based measurements, i.e. vital capacity can be compared using calibrated syringes with great accuracy, and in vivo studies are not necessary per se. Comparisons of TLC, T L,CO , V A , etc cannot be made via in vitro approaches due to the lack of suitable equipment: an in vivo comparison is the only option.
Flow parameters take up a special position, because several methods can be used. A frequently used approach is the volume measurement using syringes as described for volume parameters: the assumption is that when the measured volumes are identical the flows are too. One must acknowledge that the absolute proof of identical flows is lacking. The use of flow generators is theoretically speaking better, but such systems are not widely available, costly and bulky. Fixed flow and wave form generators can be used. The last option is of course to carry out an in vivo study (human wave form generators) (Gardner et al 1986) .
This paper describes a comparison of two lung function systems, one originating from a current manufacturer and an alternative source, to assess whether these systems are equivalent and a seamless transition is possible. Where possible and feasible, we included in vitro and in vivo methods to compare the sensitivity of these approaches.
Methods

Systems
Two manufacturers were compared: (1) Jaeger (Höchberg, Germany) which acts as the reference and (2) ZAN (Oberthulba, Germany) which is the alternative source.
The Jaeger system consists of a Masterlab bodyplethysmograph, also suited for spirometry and flow-volume curve determinations via pneumotachography, and a Pneumoscreen pneumotachograph.
Furthermore, two diffusion capacity systems are used: (1) Masterscreen CS-FRC and (2) Masterlab CompactTransfer. The ZAN system consists of a bodyplethysmograph, capable of carrying out spirometry and flow-volume curve measurements via pneumotachography. Incorporated in the bodyplethysmograph is also equipment capable of measuring T L,CO , V A and TLC via multiple breath helium dilution (Gosselink and Stam 2005, Ruppel 2004 ).
The two bodyplethysmographs harbour the same measuring principles. Both are volumeconstant plethysmographs. Using the inspiratory/expiratory flows and box pressure the airway resistance is obtained, while mouth pressure and box pressure are used to estimate ITGV. The Jaeger pneumotachographs are Lilly types with a constant resistance, while the ZAN pneumotachograph is a variable orifice system with a non-constant resistance. Both systems convert the pressure difference over the resistance airflows (Gosselink and Stam 2005, Ruppel 2004 ).
The diffusion capacity measurements were made with Masterscreen CS-FRC, which is a rolling seal spirometer. A test gas is fed to/inhaled from the spirometer and an exhalation balloon collects the exhaled air. The inhaled and exhaled gas is fed to slow-reacting CO and He analysers. With the Masterlab CompactTransfer, the test gas is fed to/inhaled from a bag and again an exhalation balloon collects the exhaled air. Again, the inhaled and exhaled gas is fed to slow-reacting CO and He analysers and a pneumotachograph is used for volume measurements. With the ZAN system, the patient inhales the gas mixture directly from the gas cylinder via a demand valve and the exhaled gas is fed directly to fast-reacting CO and He analysers; the volume measurement is done using a pneumotachograph (Gosselink and Stam 2005, Ruppel 2004 ).
In vitro study design
To asses in vitro equivalence of volumes and flows (VC, PEF, FEV 1 , MEF 75/50/25 ), three approaches were used: (1) volume measurements with a calibrated syringe, (2) flow measurements with an adjustable, fixed flow generator and (3) flow measurements with a wave form generator.
(1) A 2 litre syringe was used to assess volume accuracy and flow linearity. Several strokes (n = 9) were pumped through the pneumotachographs of the Jaeger/ZAN systems at low (=1 l s −1 ), medium (=4 l s −1 ) and high flows (=8 l s
), respectively. The measured volume was the primary parameter and it was measured without an ATPS-BTPS correction.
(2) The fixed flow generator was a Godart (Bilthoven, The Netherlands) flow generator. Flows were generated by a pump blowing air through pipes, each with a fixed resistance, and the pressure drop was measured by a gauge. The speed of the pump could be changed to obtain the correct pressure drop over the resistance resulting in flows of 0.5 l s and 5 l s −1 . All pneumotachographs were connected directly to these pipes via a short sleeve. In order to minimize any turbulence, changes in diameters were avoided. All determinations were done five-fold and no ATPS-BTPS correction was used.
(3) The wave form generator was a MH Customs Design (Midvale, USA) generator. ATS wave forms PW4, H10, H18, H21, H1 and PW15 were used (Gardner and Hankinson 1982) . To make a proper comparison, we deemed it sufficient to use five wave forms equally divided from low to high flows. We also connected the wave form generator directly to the pneumotachographs and without changes in diameter to minimize turbulence. All determinations were done five-fold and no ATPS-BTPS correction was used.
In vivo study design and lung function measurements
To assess in vivo equivalence, all test subjects underwent measurements in both systems in a randomized, cross-over way. Blinding of subjects and technicians was not attempted: differences in the appearance of the equipment are impossible to conceal. Subjects were tested on all systems within the time span of 1 h, while the same technician took all tests on all systems. Time-related and/or technician-related bias was minimized in this way.
Parameters of interest in the in vivo study were (a) VC, FVC, FEV 1 , PEF and MEF 75/50/25 , (b) TLC and RV, (c) T L,CO and V A and finally (d) R 0.5 . FEV 1 /VC and T L,CO /V A were not evaluated, because when FEV 1 , VC, T L,CO or V A should differ between the two systems, these ratios will differ automatically. The TLC/RV determination via multiple breath helium dilution was omitted from the comparison due to the time-consuming character. In the case of VC, FVC, FEV 1 , PEF, MEF 75/50/25 and TLC, the highest value of all technically acceptable attempts was selected; for RV and R 0.5 , the lowest value was selected. The mean was taken of T L,CO and V A .
All lung function measurements took into account the ERS guidelines and were carried out by experienced lung function technicians.
Subjects
The test subjects consisted of two groups: (1) a selection, randomly drawn from all patients referred for routine lung function testing (without any prior knowledge of diagnosis and/or disease severity), and (2) subjects, who took part in a lung cancer screening study which encompassed lung function measurements. These latter subjects were all male, 50 years and they smoked 20 pack years.
Statistical evaluation
Descriptive statistics (mean, SD) were calculated and analysis of variance was applied to map the differences between the systems.
In the in vivo study, all parameters on all systems could not be obtained from every subject and GLM ANOVA was used: this procedure deals with the imbalance due to missing values and delivers the so-called estimated marginal means (=imbalance-corrected means) (Kirk 1993) . All analyses of the in vivo data followed the FDA guidelines for equivalence testing, which starts with ln-transformation of the data after which GLM ANOVA is carried out (biological data are often ln-normal distributed) (European Agency for the Evaluation of Medicinal Products 2001 , Schuirmann 1987 . Factors included in the ANOVA model were 'subjects' and 'systems' and the mean square error (MSE) was used to calculate the 90% confidence interval of the ln-transformed differences between the systems. The estimated ln-transformed difference and its 90% CI were back-transformed to obtain the ratio (and 90% CI). The parameter used to claim/reject equivalence is the 90% CI: this interval contains the true population ratio of the values measured with the test/reference system. The lower or upper end of this 90% CI may not be lower/higher than the negative or positive maximum allowable difference: if they are, an equivalence claim has to be rejected either based on true inequivalence or based on insufficient statistical power (which widens the 90% CI).
To the best of our knowledge, no consensus exists on this maximum allowable difference, so the reader her/himself must/can assess whether the 90% CIs are too wide or not. For volume and flow measurements, the ATS has set an accuracy requirement of 3%, which here may be used as the maximum allowable difference. 90% CI instead of 95% CI may be used because one-sided testing is allowed in this approach: normally one tests whether values are either higher or lower than the reference, but an alternative system can only measure higher or lower. So one tests one sided at 5%, which is equivalent to a two-sided 90% CI.
The in vitro data were analysed in a similar fashion, but the data were normally distributed and ln-transformation was not needed: the listed means, SD and 90% CI are hence based on differences and not on ratios. In the ANOVA analysis of the wave form study, the type of equipment, the wave form applied and their interaction were incorporated in the ANOVA model. If this interaction is significant, the difference between the systems is dependent on the type of wave form applied and a general statement on differences (=90% CI) between the equipment is not possible. In the ANOVA model of the syringe and the adjustable, fixed flow study, the type of equipment and flow height were incorporated: this analysis followed the same principles as the wave form study.
Results
In vitro studies
As explained earlier, in these studies only volumes and flows could be compared: (1) using syringes only volume (=VC) and flow linearity, (2) using the fixed flow apparatus steady-state flows and (3) using the wave form generator PEF, FEV 1 , MEF 75/50/25 and VC and wave form dependency.
(1) The calibration syringe study. The measured volumes by the three pneumotachographs are listed in table 1. Due to the very low SD values, all differences between low, intermediate and high flows were significant (p < 0.01), which also holds for the differences between the systems. As can be seen, the measured volumes at all flows are within the 3% ATS criteria and none of the significant differences between the systems are therefore clinically irrelevant. Flow alinearity was absent.
(2) The adjustable, fixed flow study. In table 2, we depict the mean ratios of the flows as measured by the three pneumotachographs. The variability between the five successive attempts at each flow was very low for all systems (coefficient of variation <0.5%). The statistical power to detect differences was therefore very high. The differences between the three systems were very small, but significant (p < 0.001), between the applied flows of course highly significant (p < 0.001) and the system-flow interaction was non-significant (p = 0.349). The latter indicates that differences between the systems were not flow dependent and constant.
(3) The wave form generator study. In table 3, we list the outcome for the comparison between the Jaeger Masterlab pneumotachograph and the ZAN one, and in table 4 the comparison between the two Jaeger systems. The difference in measured values for all lung functions, due to the various wave forms applied, was of course significant (p < 0.001). For all parameters, the equipment by wave form interaction term was significant. This means that the differences between the systems were wave form dependent and therefore non-constant. An analysis describing the overall equipment differences and the corresponding 90% CI is now not possible. As can be seen in table 3, the VC and FEV 1 differences between these systems are of a lower magnitude than noted in, e.g., the PEF or MEFs: the time-integrated parameters seem to be less sensitive in picking up differences. The differences present between the Masterlab pneumotachograph and ZAN were also present between the Pneumoscreen and the Masterlab. As can be seen in table 4, an almost copy/paste situation is present as in table 3: the noted difference is apparently due to a different behaviour of the Jaeger Masterlab and not of the ZAN or Pneumoscreen systems.
In vivo study
In total, 59 subjects were included and in table 5 their mean lung function, expressed as a percentage of the predicted, is listed (as measured on the reference system). As can be seen, the lung function was not severely disturbed in this sample of subjects: we tried to include test subjects with a severe decreased lung function, but these subjects could not complete two or more complete cycles due to fatigue. The mean (SD) age of the subjects was 59.6 (13.4) years and 51 men were tested opposed to 8 women. In table 6, the ratios of the means of the parameters measured on either Jaeger or ZAN are listed together with their 90% CI. The point estimates of the ratio for R 0.5 and RV are very close to 100% and differences are non-significant. R 0.5 and RV measurements could be claimed equivalent if the maximum allowed difference is 13% resp. 10%. The TLC measurement can be claimed to be equivalent when the maximum allowed difference is set at 2%. This difference seems clinically acceptable. Similar conclusions can be drawn for VC, FVC and FEV 1 . The ratios for PEF and MEF 75/50/25 indicate that the ZAN PEF is lower while the MEF 75/50/25 values are higher compared to Jaeger. The width of the 90% CI is rather small, indicating sufficient statistical power and so a conclusion of true differences must be drawn.
The mean T L,CO and V A values as a percentage of the predicted are again to be found in table 5. For T L,CO , a picture emerges of inequivalence between systems, even within one and the same manufacturer: from the data in table 7 one can conclude that the Jaeger Masterscreen delivers the lowest T L,CO values, the Jaeger Masterlab intermediate ones, while ZAN takes up the highest position and the latter is significantly higher compared to the Jaeger Masterscreen. The width of all CIs is below 8%. In table 8, it is shown that for V A the differences between the systems are small, non-significant. The 90% CIs are again rather small.
Discussion
We found that not only between but also within brands of lung function equipment, significant differences in measured values exist and that such differences are sometimes only detectable via elaborate in vivo studies and/or complicated test equipment. Not all test methods in use are sufficiently sensitive, especially where flows are assessed. The differences we report were not elicited by subject variability and/or study design/conduct. As explained in the methods section, all subjects were tested within short periods of time in a randomized way. Technician bias was minimized by assigning one technician to one and the same patient. In the in vitro studies, the build-up of equipment, the connections of wave form generators, syringes, etc to the equipment are standardized. We therefore conclude that the differences we report are truly equipment related.
As pointed out earlier, there are several lung function parameters for which no in vitro test methods are available: for T L,CO , R AW , ITGV, etc, in vitro calibration is impossible in daily practice and only indirect calibration is available. With bodyplethysmographs one can assess box pressure fluctuations when pumping in/out 500 ml air and whether the measured changes are equal to those expected, but that is not as direct as measuring a known and calibrated thoracic gas volume. For T L,CO and resistance parameters, no in vitro options are available: to the best of our knowledge, no testing equipment is available. This lack of calibration equipment forces one to turn to comparative in vivo studies and although not impossible, these are hard to carry out. Many laboratories check their equipment by repeatedly measuring a few healthy subjects and assess whether changes become too large to be acceptable (i.e. so-called biological calibration). The problem with in vivo tests lies in achieving sufficient accuracy for which large sample sizes are needed, especially for those parameters which show high degrees of intra-subject variability. Accuracy is reflected in the width of, e.g., the between-systems' mean difference 90% CI; in a Bland-Altman plot a low accuracy is visible by a large distance between the upper/lower ±2 SD lines (Bland and Altman 1986) . Such a lack of accuracy often leads to a conclusion of 'statistically no significant' differences, but that does not mean that clinically significant differences are excluded: one is simply incapable of detecting such differences. We have used ≈60 subjects in an attempt to arrive at small 90% CIs and when we use the ATS 3% deviation requirement as a starting point, we must conclude that for several parameters the width of the 90% CI is larger and hence we cannot claim equivalence between the systems we tested. A >3% width means that, in the population, differences >3% are possible, which is not acceptable when using these definitions of allowable differences. One might now remark that a 3% requirement is a too harsh one and that for resistance parameters larger differences are allowable. That is not an unreasonable statement, but at this moment no one has defined what differences between equipment are allowable. In the field of lung function testing, with its large number of brands, the need for such limits is clearly present. Definition of such equivalence limits (either for in vitro or for in vivo studies), combined with the intra-subject variability, dictates the study sample size and testing methods with insufficient size or accuracy automatically betray themselves by reporting too wide 90% CI: the researcher/pulmonologist can easily weigh that information. A too wide interval automatically prevents claiming equivalence and only well-powered studies can do so: their 90% CIs are sufficiently small.
We feel that more emphasis must be paid in the near future on in vitro methods because these approaches harbour the possibility of showing low degrees of variability; the latter will always frustrate in vivo comparisons. Next to that when such in vitro methods are available and sufficiently validated, they can become a worldwide standard. After all, the lack of such a standard opens the possibility that brands A and B can be shown to be equivalent, B and C too, but A and C appear not to be. B is somewhat lower than A and C is somewhat lower than B and so C can be significantly lower than A. Such a multi-stage testing is preferably avoided.
A second finding of this study is that not all in vitro methods are sufficiently sensitive. We could compare four methods for flow testing and only the wave form generator and the in vivo study concluded that differences were present, where the syringe and fixed flow approaches failed to show these. By reporting this, we can confirm the findings by Nelson et al (1990) . In this light, it is unfortunate that the two most sensitive methods are also the most difficult ones: either large studies or large pieces of equipment are needed, the very reasons why in daily practice only syringe testing is done routinely. The reason why these differences in sensitivity are present is, we feel, not so hard to give. All flow measuring equipment will be put on the rack, when flows steeply rise to high magnitudes, e.g. peak flows. Both the syringe and the fixed flow approach are not capable of simulating these phenomena: the dynamic features of flow sensors are simply insufficiently probed and deviations not recognized. To illustrate this, the differences we found (higher peak flow and lower MEF 50 values) were due to a malfunctioning flow sensor. This sensor harbours a metal membrane which is connected to a small rod, moving from left to right in an electric coil. The pressure drop over the flow sensor resistor is translated into movements of that membrane: the pressure generated by the patient is fed to the left side of the membrane and the atmospheric pressure to the right side. Blowing into the mouthpiece forces the membrane to move to the right. This membrane proved to show a snap-like behaviour: when pressure was applied to the patient inlet, it suddenly snapped to the right, overshooted and subsequently snapped back, again with an overshoot. Translated in flows: a too high peak flow and, due to snapping back, 'lowered' MEF 50 values. Such behaviour cannot be made visible when the rise of the flow is slow. Wave form generators, either in a mechanical or in a human form, show steeply rising flows, the other systems do not. Parameters such as FEV 1 and VC are derived from integration of flows into volumes over time that makes them less suited to serve as parameters for flow calibration. The overshoot we described above will tend to be invisible with these time-integrated parameters: the early excess and the later shortage will balance and both FEV 1 and VC are minimally influenced.
The reasons why the T L,CO measurements deviated must be sought in the software handling of measured data. The fact that the V A values turned out be very similar eliminates a lot of sources of possible error. Lung distribution and handling of test gases are not to blame, the way the tests were carried out is not to blame as well as the measurements of inhaled/exhaled volumes. All systems take care of offset in sensors and/or test gas concentrations by verifying the sensors prior to the actual measurements using the actual CO and He concentrations as delivered to the subjects. Only parameters linked to measuring exhaled CO levels and their processing by the software must be culpable. Enquiring with the manufacturers showed that the software contains several rather unknown correction factors and the validity of such factors is often not well documented. They can differ from brand to brand (in type and magnitude) and within brands from one type of equipment to another or from one software version to another. Which of the systems tested here delivers the correct T L,CO remains to be seen: the effects of the lack of a golden standard are evident.
These observations of deviating lung function values due to differences between and within brands must lead to precautions. Disease is often signalled by crossing upper or lower thresholds, and e.g. for T L,CO , switching from ZAN to the Jaeger Masterscreen would lead to much more subjects being labelled as diseased or the disease status deteriorates. Alternatively, the probability to detect disease, by using the higher ZAN T L,CO values, would be lowered. There is no easy solution for these problems. Of course, one might generate one's own reference values but as said earlier this requires large samples of healthy subjects, ranging from young to old. In regression analysis, frequently a ratio between the number of parameters and cases of 1:10 is used to ensure proper extrapolation and to avoid overfitting. If one now has 20 age classes and in each class height and sex are used as explanatory variables, 20 × 2 × 10 = 400 subjects minimally are needed (Stevens 1996) . One will agree that this is a very impractical situation. Again a step forward is, in our opinion, the use of validated in vitro golden standards.
In multi-centre clinical studies, proper statistical evaluation may solve this problem by incorporating in the statistical (ANOVA) model centres as a main factor. Differences between centres are then accounted for and do no longer bias the outcome measures. The drawback is that the power to detect differences between centres must be sufficiently large, so sample sizes per centre must be sufficiently large.
To summarize, we sometimes found significant differences between and within brands of lung function equipment and next to that not all testing methods are sufficiently sensitive. The need for validated and widely accepted in vitro calibration systems is evident, because in vivo comparisons are impractical. 
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